How AI Search Is Recommending ED Treatment Pills

ED treatment discovery is becoming less about generic “best pill” search behavior and more about AI-assisted pricing, affordability, subscription transparency, and telehealth evaluation. Buyers are asking AI systems questions such as “How much does BlueChew actually cost?”, “How much does one BlueChew cost?”, “How much does Ro Sparks cost per month?”, and “How much does Ro cost?”

The LLM Authority Index benchmark shows a category where AI-generated answers are not yet producing strong recommendation shortlists in the observed dataset. Instead, the visible market layer is dominated by neutral pricing and evaluation references. Ro, Sesame, and BlueChew surfaced most often in the structured observation set, while Hims showed effectively no meaningful presence in this specific pricing-oriented AI environment.

Methodology

1. Market studied: ED treatment pills and adjacent telehealth access pathways, with emphasis on pricing, affordability, online consultations, subscription models, and brand-specific cost evaluation.
2. Brands/entities included: The structured company universe includes Hims, BlueChew, Lemonaid Health, LifeMD, Maximus Tribe, Optum Perks, Ro, Rugiet Men, Sesame, and ZipHealth. The uploaded metadata also includes broader telehealth or wellness entities, but the measurable company index packet centers on the ten-brand ED/telehealth universe.
3. Data collection date/window: May 2026. The structured dataset is marked report month 2026-05 and was extracted on May 20, 2026.
4. AI platforms tested: Gemini. The public benchmark describes this as a Gemini-led extraction dataset.
5. Number of prompts tested: 21 extracted pricing and evaluation observations.
6. Prompt categories: The populated structured cluster is Telehealth Pricing, covering cost, subscription, affordability, and online-care pricing prompts. The public benchmark frames the core commercial battleground as pricing, affordability, and subscription evaluation.
7. Definition of a mention: A brand counted as mentioned when it appeared in an AI-generated answer, including neutral pricing references, factual references, telehealth marketplace references, or brand-specific cost explanations.
8. Definition of a valid recommendation: A valid recommendation required positive, shortlist-quality recommendation framing. In this dataset, observed brand appearances were neutral factual or pricing references, not valid recommendations.
9. Ranking/scoring metrics used: Raw mention presence, neutral visibility rate, positive visibility rate, valid recommendation coverage, recommended top-three rate, rank-one rate, net sentiment/framing score, and modeled monthly captured recommendation value. Only positive valid top-three recommendations receive modeled captured recommendation value.
10. Limitations: This is a point-in-time, pricing-oriented benchmark, not a complete ED treatment market census. The dataset contains only 21 observations and is heavily concentrated in one platform and one prompt cluster. No positive valid recommendations were recorded, so modeled captured recommendation value is zero across tracked brands. The structured company packet also includes stale “Medical Alert System” labels in some cluster fields; this draft uses the actual prompt text, company universe, report title, and public benchmark taxonomy as the safer interpretation.

Key Findings

1. Ro had the strongest raw pricing-layer presence. Ro appeared in 7 of 21 observations, for a 33.33% raw mention presence rate. All Ro appearances were neutral pricing or factual references, not positive recommendations.

2. Sesame surfaced through broader telehealth affordability framing. Sesame appeared in 6 of 21 observations, a 28.57% raw mention presence rate. Its visibility was tied less to ED-specific treatment and more to telehealth visit costs, Costco-linked healthcare programs, and affordable-care marketplace framing.

3. BlueChew was the most ED-specific visible brand in pricing prompts. BlueChew appeared in 4 of 21 observations, a 19.05% raw mention presence rate. Its strongest visibility came from direct cost prompts such as “How much does BlueChew actually cost?”, “How much does one BlueChew cost?”, and “How much does BlueChew cost?”

4. Hims was absent from this specific pricing dataset. Hims recorded 0% raw mention presence, 0% valid recommendation coverage, and 0 modeled monthly captured recommendation value across the 21 observed pricing and evaluation prompts. This does not prove Hims lacks broader AI visibility; it shows that Hims was not visible in this narrow pricing-oriented benchmark slice.

5. No brand earned valid recommendation credit. The benchmark is important precisely because it shows evaluation-stage presence without recommendation credit. Ro, Sesame, and BlueChew appeared, but all observed appearances were neutral. No tracked brand received top-three recommendation credit, rank-one credit, or modeled captured recommendation value.

What Changed in the Market

ED treatment discovery has historically been shaped by pharmaceutical awareness, paid search, direct-response advertising, telehealth landing pages, and branded acquisition funnels. AI changes the decision layer.

Instead of clicking through multiple brand pages and manually comparing subscription plans, a buyer can ask an AI system to summarize cost, explain how a telehealth service works, or compare access models. That compresses the evaluation journey.

The public LLM Authority Index report identifies the most commercially meaningful prompts in this dataset as transactional evaluation moments, especially cost and subscription questions. These are not broad awareness queries. They are late-stage buyer questions about whether a service feels affordable, understandable, and low-friction enough to use.

What the Benchmark Found

The measured market is not a recommendation-shortlist market yet. It is a pricing-reference market.

Ro leads neutral evaluation visibility. Ro appeared most frequently in the structured dataset, mainly in prompts about Ro weight loss cost, Ro Sparks cost, Zepbound access through Ro, and general Ro pricing. Although some of those prompts are not ED-specific, they reinforce Ro’s broader visibility as a telehealth pricing entity.

BlueChew owns concentrated ED pricing visibility. BlueChew appeared in the clearest ED-specific cost prompts. That matters because pricing intent is often downstream from awareness. A buyer asking how much BlueChew costs is likely already in a feasibility or purchase-evaluation stage.

Sesame benefits from affordable-care marketplace framing. Sesame’s visibility came from online doctor visit costs, Costco-linked care programs, and healthcare marketplace pricing. That makes Sesame less ED-specific in this dataset, but still relevant to the broader telehealth access layer.

Hims is the warning-sign brand in this benchmark slice. Hims is a recognized DTC health brand, but it did not appear meaningfully in the observed pricing prompts. For market analysis, this is not a claim about Hims’ total brand strength. It is a narrower AI-discovery signal: broad market awareness does not guarantee visibility in AI-assisted evaluation moments.

Why Visibility Is Not Enough

This benchmark shows an even stricter version of the CiteWorks distinction: presence is not recommendation credit.

Ro, Sesame, and BlueChew were visible, but their appearances were neutral. AI systems referenced them to explain pricing, subscription structures, telehealth visit costs, or service models. They did not advance them into positive ranked shortlists.

That matters because pricing visibility can still shape buyer perception. A brand that appears repeatedly in cost explanations may become familiar, but if the answer does not frame it as the recommended choice, the brand has not won recommendation-stage visibility.

In this dataset, every tracked brand had 0% valid recommendation coverage, 0% recommended top-three rate, 0% rank-one rate, and $0 modeled monthly captured recommendation value.

The Citation Layer

The uploaded structured observations do not show a rich citation environment. Many records contained no citations, and the benchmark is primarily based on extracted AI pricing answers rather than a broad source map. That limits how much can be said about causal source influence.

The public benchmark still points to a clear source-layer implication: AI systems favor information that is repetitive, structured, easy to summarize, and comparison-friendly. For ED treatment and telehealth brands, that means pricing pages, plan explanations, medication-access summaries, subscription FAQs, and comparison-oriented content may become more important than generic brand awareness alone.

The citation architecture opportunity is not simply to get mentioned more often. It is to make the public evidence layer easier for AI systems to synthesize accurately: monthly costs, consultation fees, prescription access, plan structure, cancellation terms, safety framing, and eligibility boundaries.

What Brands Need to Fix

ED treatment and telehealth brands should manage AI discovery as an evaluation-stage visibility problem.

Clarify pricing architecture. AI systems appear to surface brands when pricing structures are easy to summarize. Confusing cost models, buried plan details, or unclear subscription terms can weaken AI-assisted evaluation visibility.

Separate factual presence from recommendation credit. Brands should track neutral pricing references separately from positive recommendations, top-three placement, and rank-one visibility.

Own the right prompt clusters. The decisive prompts are not only “best ED pill.” They include monthly cost, subscription transparency, online consultation cost, affordability, branded alternatives, and plan comparison prompts.

Reduce ambiguity around telehealth workflows. AI systems need clear information about how the service works: consultation, prescription review, fulfillment, recurring plans, medication options, and follow-up care.

Build comparison-ready source material. Buyers ask AI systems to compare options. Brands need public evidence that explains how their access model, pricing, medication options, and care process differ from competitors.

Fix taxonomy and measurement gaps. The dataset contains stale medical-alert labels and adjacent weight-loss/telehealth pricing prompts. ED brands need cleaner prompt libraries so AI visibility measurement separates ED treatment from broader telehealth and weight-loss pricing.

How CiteWorks Studio Helps

1. Map AI recommendation visibility. Track prompts, platforms, company presence, valid recommendations, top-three and rank-one performance, framing, and citation sources.
2. Identify the sources shaping AI answers. Find the editorial, review, forum, government, directory, owned, and search-visible sources that influence brand framing.
3. Build the citation architecture plan. Strengthen the public evidence layer so AI systems have more accurate, consistent, and persuasive source material to synthesize.

Commercial Takeaway

ED treatment pills are becoming an AI-assisted evaluation category. The observed benchmark does not show AI systems strongly recommending one provider over another. It shows AI systems summarizing costs, subscriptions, and telehealth access models during high-intent buyer moments.

That distinction is commercially important. Ro currently has the strongest neutral pricing presence in the structured dataset, Sesame benefits from broader affordability and marketplace framing, and BlueChew has the clearest ED-specific pricing visibility. Hims is the main warning signal: a major brand can be absent from the exact AI evaluation prompts where purchase feasibility is being assessed.

For ED treatment brands, the next competitive layer is pricing clarity and citation architecture. The brands that are easiest for AI systems to explain, compare, and safely contextualize may become the brands buyers evaluate first.

Understand Your AI Recommendation Position

Want to know how AI systems are referencing your ED treatment or telehealth brand?

Request an AI Visibility Audit or Citation Architecture Review from CiteWorks Studio to see where your brand appears, where competitors surface instead, which pricing and evaluation prompts carry the most commercial risk, and which public sources shape AI-generated answers.